2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156255
    MAO-B-IN-25 2097148-47-3 ≥98.0%
    MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC50s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively.
    MAO-B-IN-25
  • HY-156429
    MK-1468 2769107-89-1 99.69%
    MK-1468 is an orally active, selective, and BBB-permeable LRRK2 inhibitor. MK-1468 can be used for the research of Parkinson's disease.
    MK-1468
  • HY-15780S
    Brexpiprazole-d8 1427049-21-5 ≥99.0%
    Brexpiprazole-d8 (OPC-34712-d8) is the deuterium labeled Brexpiprazole (HY-15780). Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM).
    Brexpiprazole-d8
  • HY-157956
    LASSBio-873 873694-54-3 99.82%
    LASSBio-873 is an orally active muscarinic cholinergic receptor (mAChR) agonist that crosses the blood-brain barrier. LASSBio-873 has potent analgesic effects on acute and inflammatory pain. The analgesic effect of LASSBio-873 can be inhibited by intrathecal injection of the M2 receptor antagonist methoctramine.
    LASSBio-873
  • HY-159083
    DN5355 937012-09-4 99.01%
    DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease.
    DN5355
  • HY-160842
    CSF1R-IN-24 3024322-57-1 98.10%
    CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG).
    CSF1R-IN-24
  • HY-160903
    Suzetrigine phenol 2649467-91-2 99.39%
    Suzetrigine phenol is the phenolate form of the sodium channel modulator Suzetrigine (HY-148800). Suzetrigine (VX-548) is an orally active and highly selective inhibitor of NaV1.8.
    Suzetrigine phenol
  • HY-161104
    Kv2.1-IN-1 2252448-93-2 98.64%
    Kv2.1-IN-1 (compound 80) is a potent inhibitor of Kv2.1, with the IC50 value of 0.07 μM, selectivity >130 fold over other K+, Na+, and Ca2+ ion channels.
    Kv2.1-IN-1
  • HY-161683
    Tyk2-IN-19 2866415-98-5 98.62%
    Tyk2-IN-19 (Compound 1) is an orally active and blood-brain barrier (BBB) permeable Tyk2 inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases.
    Tyk2-IN-19
  • HY-161723
    LH2-051 2358754-22-8 99.85%
    LH2-051 is a lysosome-enhancing lead compound, which promotes the lysosome biogenesis and the Aβ aggregate clearance through dopamine transporter-cyclin-dependent kinase 9-transcription factor EB (DAT-CDK9-TFEB) pathway. LH2-051 exhibits good pharmacokinetic characteristics in mouse models. LH2-051 is potential for ameliorating Aleheimer’s Disease.
    LH2-051
  • HY-162452
    Prolyl endopeptidase inhibitor 2 2362592-81-0 98.37%
    Prolyl endopeptidase inhibitor 2 (Compound 8) was a proline endopeptidase (PEP) inhibitor with IC50 value 31.11 μM. Prolyl endopeptidase inhibitor 2 can be used in the study of neurodegenerative diseases.
    Prolyl endopeptidase inhibitor 2
  • HY-162683
    (S)-PHA533533 437982-89-3 98.27%
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice.
    (S)-PHA533533
  • HY-163097
    ZCAN262 99.93%
    ZCAN262 (compound 6 ) is an AMPA modulator. ZCAN262 prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site.
    ZCAN262
  • HY-163145
    α-Synuclein inhibitor 11 ≥98.0%
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research.
    α-Synuclein inhibitor 11
  • HY-163733
    AKU-005 1515855-85-2 99.48%
    AKU-005 is a FAAH and MAGL dual inhibitor with IC50 values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia.
    AKU-005
  • HY-167832
    PT109 2059104-90-2 99.20%
    PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity.
    PT109
  • HY-169116
    D5R agonist 1 99.83%
    D5R agonist 1 (Compound 5j) is a selective, orally active and BBB penetrable D5R partial agonist (EC50: 269.7 nM). D5R agonist 1 enhances the cognition in the Scopolamine (HY-N0296)-induced amnesia model.
    D5R agonist 1
  • HY-169345
    VU6043653 3032791-06-0 99.97%
    VU6043653 is a potent, selective and cross the blood-brain barrier metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC50 value of 325 nM for h mGlu5.
    VU6043653
  • HY-170035
    GlcCer (d18:1/18:0) 95119-86-1 99.58%
    GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipid. GlcCer (d18:1/18:0) is promising for research of Parkinson disease and dementia with Lewy bodies.
    GlcCer (d18:1/18:0)
  • HY-17038S
    Agomelatine-d6 1079389-42-6 98.57%
    Agomelatine-d6 is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors .
    Agomelatine-d6
Cat. No. Product Name / Synonyms Application Reactivity